Previous Topic Neurology Home
This week, we will discuss multiple sclerosis. MS is not seen frequently in clinical practice; however, there are a handful of specific drugs for this condition that you should be familiar with for the boards. There is a lot of great information in the pre-class videos, but as always, please focus on the learning objectives to not get overwhelmed.
Special thanks to Dr. Marissa Henrickson, PharmD, for recording the videos for this session.
Learning Objectives
1) Describe the pathophysiology of multiple sclerosis and recognize the associated signs and symptoms
2) Compare and contrast between sphingosine 1-phosphate receptor modulators (fingolimod) and immune-modulating monoclonal antibodies (alemtuzumab and natalizumab)
3) Develop an evidence-based therapeutic plan, including treatment goals and monitoring parameters, for newly diagnosed primary progressive MS